Lackmann M - Search Results

1

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW. Day BW, et al. Among authors: lackmann m. Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007. Cancer Cell. 2013. PMID: 23410976 Free article.

2

Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3.

Day B, To C, Himanen JP, Smith FM, Nikolov DB, Boyd AW, Lackmann M. Day B, et al. Among authors: lackmann m. J Biol Chem. 2005 Jul 15;280(28):26526-32. doi: 10.1074/jbc.M504972200. Epub 2005 May 18. J Biol Chem. 2005. PMID: 15901737 Free article.

3

Signals from Eph and ephrin proteins: a developmental tool kit.

Boyd AW, Lackmann M. Boyd AW, et al. Among authors: lackmann m. Sci STKE. 2001 Dec 11;2001(112):re20. doi: 10.1126/stke.2001.112.re20. Sci STKE. 2001. PMID: 11741094 Review.

4

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW. Charmsaz S, et al. Among authors: lackmann m. Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6. Leukemia. 2017. PMID: 27922598

5

Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling.

Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewood PF, Lackmann M. Lawrenson ID, et al. Among authors: lackmann m. J Cell Sci. 2002 Mar 1;115(Pt 5):1059-72. doi: 10.1242/jcs.115.5.1059. J Cell Sci. 2002. PMID: 11870224

6

Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen.

Smith FM, Vearing C, Lackmann M, Treutlein H, Himanen J, Chen K, Saul A, Nikolov D, Boyd AW. Smith FM, et al. Among authors: lackmann m. J Biol Chem. 2004 Mar 5;279(10):9522-31. doi: 10.1074/jbc.M309326200. Epub 2003 Dec 2. J Biol Chem. 2004. PMID: 14660665 Free article.

7

Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.

Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM, Lackmann M. Vearing C, et al. Among authors: lackmann m. Cancer Res. 2005 Aug 1;65(15):6745-54. doi: 10.1158/0008-5472.CAN-05-0758. Cancer Res. 2005. PMID: 16061656

8

Therapeutic targeting of EPH receptors and their ligands.

Boyd AW, Bartlett PF, Lackmann M. Boyd AW, et al. Among authors: lackmann m. Nat Rev Drug Discov. 2014 Jan;13(1):39-62. doi: 10.1038/nrd4175. Nat Rev Drug Discov. 2014. PMID: 24378802 Review.

9

Eph/Ephrin membrane proteins: a mammalian expression vector pTIg-BOS-Fc allowing rapid protein purification.

Day BW, Smith FM, Chen K, McCarron JK, Herath NI, Lackmann M, Boyd AW. Day BW, et al. Among authors: lackmann m. Protein Pept Lett. 2006;13(2):193-6. doi: 10.2174/092986606775101625. Protein Pept Lett. 2006. PMID: 16472084

10

Eph, a protein family coming of age: more confusion, insight, or complexity?

Lackmann M, Boyd AW. Lackmann M, et al. Sci Signal. 2008 Apr 15;1(15):re2. doi: 10.1126/stke.115re2. Sci Signal. 2008. PMID: 18413883 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page